Evidence map›Paper›PMID 30453880›Full record

ArticleBMC bioinformatics2018

Comparing the performance of selected variant callers using synthetic data and genome segmentation.

Xiaopeng Bian, Bin Zhu, Mingyi Wang, Ying Hu, Qingrong Chen, Cu Nguyen, Belynda Hicks, Daoud Meerzaman

Open access · goldAbstract read
In one paragraph

Article in BMC bioinformatics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
1.5field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 53 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Xiaopeng BianCenter for Biomedical Informatics and Information Technology, National Cancer Institute, Rockville, MD, 20850, USA. bianxi@mail.nih.gov.
Bin ZhuCancer Genomics Research Laboratory(CGR), Division of Cancer Epidemiology and Genetics, Frederick National Laboratory for Cancer Research sponsored by the National Cancer Institute, 8717 Grovemont Circle, Gaithersburg, MD, 20877, USA.
Mingyi WangCancer Genomics Research Laboratory(CGR), Division of Cancer Epidemiology and Genetics, Frederick National Laboratory for Cancer Research sponsored by the National Cancer Institute, 8717 Grovemont Circle, Gaithersburg, MD, 20877, USA.
Ying HuCenter for Biomedical Informatics and Information Technology, National Cancer Institute, Rockville, MD, 20850, USA.
Qingrong ChenCenter for Biomedical Informatics and Information Technology, National Cancer Institute, Rockville, MD, 20850, USA.
Cu NguyenCenter for Biomedical Informatics and Information Technology, National Cancer Institute, Rockville, MD, 20850, USA.
Belynda HicksCancer Genomics Research Laboratory(CGR), Division of Cancer Epidemiology and Genetics, Frederick National Laboratory for Cancer Research sponsored by the National Cancer Institute, 8717 Grovemont Circle, Gaithersburg, MD, 20877, USA.
Daoud MeerzamanCenter for Biomedical Informatics and Information Technology, National Cancer Institute, Rockville, MD, 20850, USA. meerzamd@mail.nih.gov.
National Cancer Institute · USFrederick National Laboratory for Cancer Research · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHigh-throughput sequencing has rapidly become an essential part of precision cancer medicine. But validating results obtained from analyzing and interpreting genomic data remains a rate-limiting factor. The gold standard, of course, remains manual validation by expert panels, which is not without its weaknesses, namely high costs in both funding and time as well as the necessarily selective nature of manual validation. But it may be possible to develop more economical, complementary means of validation. In this study we employed four synthetic data sets (variants with known mutations spiked into specific genomic locations) of increasing complexity to assess the sensitivity, specificity, and balanced accuracy of five open-source variant callers: FreeBayes v1.0, VarDict v11.5.1, MuTect v1.1.7, MuTect2, and MuSE v1.0rc. FreeBayes, VarDict, and MuTect were run in bcbio-next gen, and the results were integrated into a single Ensemble call set. The known mutations provided a level of "ground truth" against which we evaluated variant-caller performance. We further facilitated the comparison and evaluation by segmenting the whole genome into 10,000,000 base-pair fragments which yielded 316 segments.

resultsDifferences among the numbers of true positives were small among the callers, but the numbers of false positives varied much more when the tools were used to analyze sets one through three. Both FreeBayes and VarDict produced strikingly more false positives than did the others, although VarDict, somewhat paradoxically also produced the highest number of true positives. The Ensemble approach yielded results characterized by higher specificity and balanced accuracy and fewer false positives than did any of the five tools used alone. Sensitivity and specificity, however, declined for all five callers as the complexity of the data sets increased, but we did not uncover anything more than limited, weak correlations between caller performance and certain DNA structural features: gene density and guanine-cytosine content. Altogether, MuTect2 performed the best among the callers tested, followed by MuSE and MuTect.

conclusionsSpiking data sets with specific mutations -single-nucleotide variations (SNVs), single-nucleotide polymorphisms (SNPs), or structural variations (SVs) in this study-at known locations in the genome provides an effective and economical way to compare data analyzed by variant callers with ground truth. The method constitutes a viable alternative to the prolonged, expensive, and noncomprehensive assessment by expert panels. It should be further developed and refined, as should other comparatively "lightweight" methods of assessing accuracy. Given that the scientific community has not yet established gold standards for validating NGS-related technologies such as variant callers, developing multiple alternative means for verifying variant-caller accuracy will eventually lead to the establishment of higher-quality standards than could be achieved by prematurely limiting the range of innovative methods explored by members of the community.

Indexed as

Genome, HumanMutationPolymorphism, Single NucleotideGenomicsHigh-Throughput Nucleotide SequencingHumansMolecular Sequence AnnotationPrecision Medicine

Identifiers

PMID30453880
PMCPMC6245711
OpenAlexW2901405010

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.